Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluriaBernd Höppe, Craig B. Langman, David McDougall et al.|Kidney International|2021Cited by 90